Kazandjian D, et al. - In this exploratory pooled analysis, researchers used data from 11 metastatic non–small cell lung cancer (mNSCLC) randomized clinical multinational trials, including 3,987 patients with available data to investigate if there is a relationship between the lung immune prognostic index composite (LIPI) score (the derived neutrophil to lymphocyte ratio and the lactate dehydrogenase level) and long-term results among mNSCLC patients treated with immune checkpoint inhibitors (ICIs), targeted therapy (TT), or cytotoxic chemotherapy (CCT). Findings revealed the link between the LIPI score and overall survival (OS) and progression-free survival (PFS) among patients taking either ICIs, TT, or CCT. Better OS was observed in relation to a good LIPI score vs poor LIPI scores among patients receiving ICIs, TT, and CCT. For PFS, similar results were documented. Regardless of treatment modality, baseline lactate dehydrogenase level and derived neutrophil to lymphocyte ratio were identified as significant prognostic biomarkers.